pwshub.com

Bayer wins victory in US legal battle against Roundup cancer claims

By Jonathan Stempel

(Reuters) - Bayer won a legal victory in its fight to limit liability from claims that its Roundup weed killer causes cancer, as a U.S. appeals court on Thursday said federal law shields the German company from a lawsuit by a Pennsylvania landscaper.

The 3rd U.S. Circuit Court of Appeals in Philadelphia rejected plaintiff David Schaffner's claim that Bayer's Monsanto unit violated state law by failing to put a cancer warning on the label for Roundup.

Schaffner was diagnosed in 2006 with a kind of cancer called non-Hodgkins lymphoma, a common claim for Roundup plaintiffs.

He and his wife Theresa sued Bayer in 2019, in part over how his illness affected their relationship.

Chief Judge Michael Chagares wrote for a unanimous three-judge panel that the Federal Insecticide, Fungicide, and Rodenticide Act requires nationwide uniformity in pesticide labels, and prevented Pennsylvania from adding a cancer warning.

Bayer said the decision conflicts with rulings from federal appeals courts in San Francisco and Atlanta in similar cases.

That may increase the prospect that the U.S. Supreme Court could step in to resolve the split, and potentially reduce Bayer's liabilities.

Chip Becker, a lawyer for the Schaffners, said he was disappointed with the decision, and that federal law should not preempt his clients' failure-to-warn claim. He said the Schaffners are reviewing their legal options.

Bayer said it was pleased with the decision, and the Supreme Court should "settle this important issue of law."

It has maintained that Roundup and its active ingredient glyphosate are safe, and said it "continues to stand fully behind" the brand.

Bayer has faced extensive litigation over Roundup, and has seen its share price fall more than 73% since buying Monsanto for $63 billion in June 2018.

The company settled much of the Roundup litigation for $10.9 billion in 2020, but still faces about 58,000 claims. Another 114,000 claims have been settled or deemed ineligible.

Though Bayer won 14 of 23 Roundup trials through July 23, one victory was overturned on appeal, and the losses saddled it with billions of dollars of damages awards.

The Schaffners settled with Bayer in September 2022, conditioned on Bayer being unable to convince courts that federal law preempted Pennsylvania from requiring a cancer warning.

Chagares said it did, and that this approach "best achieves Congress's stated aim of uniformity in pesticide labeling."

Roundup is among the most widely used weed killers in the United States. Bayer phased out sales for home use last year.

The case is Schaffner et al v Monsanto Corp, 3rd U.S. Circuit Court of Appeals, No. 22-3075.

(Reporting by Jonathan Stempel in New York; Additional reporting by Brendan Pierson; editing by Jonathan Oatis)

Source: finance.yahoo.com

Related stories
1 day ago - Presidents can move entire markets with a single sentence. Donald Trump, a former president, sent a single stock soaring with just three words: “I’m...
1 month ago - A powerful rally has lifted Japan's Nikkei and Asian stock markets, and European and U.S. stock futures indicate they will follow too. Given the confluence of factors that drove the selloff - Japan's rate hike, an unwind of yen-funded...
1 month ago - Open-source data science platform provider Knime AG said today it has closed on a new, $30 million investment from its longtime backer Invus. The round is the first major investment the company has received since Invus led its initial...
1 month ago - (Bloomberg) -- Global stocks rose on Friday, with sentiment buoyed by growing optimism that the US will avoid a recession. Most Read from BloombergManchester Is Giving London a Run for Its MoneyBoston’s Broke and Broken Transit System...
1 month ago - Recursion Pharmaceuticals (NASDAQ: RXRX) and Exscientia (NASDAQ: EXAI) made waves on Aug. 8 when they announced plans to merge into one business,...
Other stories
20 minutes ago - European auto stocks are so unpopular right now that investors keep reducing their exposure even as the scale of the industry's problems has driven valuations close to record lows, which would normally be a big incentive for would-be...
20 minutes ago - Investors should always rely on their own analysis, not just management talk and projections, when deciding whether to buy a stock.
1 hour ago - As the Federal Reserve kicks off a long-awaited rate cutting cycle, some investors are wary that richly valued U.S. stocks may have already priced in the benefits of easier monetary policy, making it harder for markets to rise much...
1 hour ago - Shares of cybersecurity company CrowdStrike (NASDAQ:CRWD) jumped 5.9% in the morning session as markets roared back after an initially muted response to the Fed's rate cut, which sparked a renewed appetite for risk assets. While investors...
3 hours ago - (Bloomberg) -- Asian stocks extended a rally in global equities as jobs data backed the view that the US economy is headed for a soft landing. The yen gained as the Bank of Japan left interest rates unchanged.Most Read from BloombergAOC...